As of mid-August 2026, trader consensus heavily favors no new coronavirus pandemic this year, with COVID-19 activity remaining at endemic levels characterized by very low emergency department visits (0.3%) and modest Rt estimates around 1.08 indicating slow growth from a minimal baseline. Official surveillance from the CDC and WHO shows no novel coronavirus spillover or variant capable of triggering widespread severe disease and global transmission, consistent with the post-2023 transition to seasonal circulation. This evidence supports the 94.8% implied probability of "No," reflecting accumulated immunity, ongoing monitoring, and absence of concerning signals through summer. However, scenarios such as rapid evolution in emerging pathogens like canine coronavirus or a highly immune-evasive SARS-CoV-2 sublineage could alter trajectories if surveillance detects sustained human-to-human spread before year-end.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourNouvelle pandémie de coronavirus en 2026 ?
Oui
$22,844 Vol.
$22,844 Vol.
Oui
$22,844 Vol.
$22,844 Vol.
The resolution source will be official announcements from the World Health Organization.
Marché ouvert : Jan 6, 2026, 2:40 PM ET
Resolver
0x65070BE91...The resolution source will be official announcements from the World Health Organization.
Resolver
0x65070BE91...As of mid-August 2026, trader consensus heavily favors no new coronavirus pandemic this year, with COVID-19 activity remaining at endemic levels characterized by very low emergency department visits (0.3%) and modest Rt estimates around 1.08 indicating slow growth from a minimal baseline. Official surveillance from the CDC and WHO shows no novel coronavirus spillover or variant capable of triggering widespread severe disease and global transmission, consistent with the post-2023 transition to seasonal circulation. This evidence supports the 94.8% implied probability of "No," reflecting accumulated immunity, ongoing monitoring, and absence of concerning signals through summer. However, scenarios such as rapid evolution in emerging pathogens like canine coronavirus or a highly immune-evasive SARS-CoV-2 sublineage could alter trajectories if surveillance detects sustained human-to-human spread before year-end.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour



Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes